Revised bill on NPs serves as reminder of challenges
After failing to gain enough support in a California Assembly, a revised bill that allows nurse practitioners to operate independently only in a hospital, clinic or other group setting regained some of its momentum and advanced in the assembly.
With the introduction of Senate Bill 941, as well as proposed legislation that is currently pending in several other states, it is clear that lawmakers are increasingly recognizing the vital role that nurse practitioners play. They also are realizing that expanding nurse practitioners’ scope of practice will only become increasingly important as millions of uninsured Americans come into the insurance fold in 2014 due to health reform amid a growing shortage of primary care physicians.
According to a team of researchers in a report titled “Projecting U.S. Primary Care Physician Workforce Needs: 2010-2015,” after incorporating insurance expansion, the United States will require nearly 52,000 additional primary care physicians by 2025.
While it is clear that lawmakers are taking note of the important role that nurse practitioners play in an already strained healthcare system, it is also evident that there’s much more work to be done to overcome resistance.
In its original version, Senate Bill 941 aimed to establish independent practice for NPs, enabling them to perform all tasks and functions consistent with their education and training. It wasn’t until the bill was revised and narrowed — removing a trail to independent practice without physician oversight after more than 6,000 hours of supervised practice — that it advanced in the Assembly.
“…These changes undermine the very heart of the legislation’s original objectives, creating additional, unnecessary regulatory roadblocks just as national healthcare reform is necessitating that the industry streamline care delivery models…” stated The American Association of Nurse Practitioners presidents Angela Golden and Kenneth Miller in a prepared statement.
The reality is that the spotlight remains fixed on scope of practice and how Americans can gain greater access to quality, convenient and cost-effective healthcare services. It is an issue that won’t fade away any time soon.
NACDS announces winners of Total Store Expo Product Showcase
ARLINGTON, Va. — The National Association of Chain Drug Stores has announced the winners of the 2013 NACDS Total Store Expo Product Showcase.
The 160 products, ranging from health and beauty to seasonal items, were on display in the “Product Showcase” on the exhibit floor. The Showcase provided increased visibility for suppliers marketing products.
Evaluated by the retail attendees, winners of this year’s “Product Showcase” are:
Company/booth: Fleet Laboratories / Booth 3240
Product: Boudreaux’s Butt Paste
Company/booth: The Jel Sert Company / Booth 3249
Product: Super C Vitamin Drink Mix
Cosmetics & Fragrances
Company/booth: Beauty 21 / LA Colors / LA Girl / Booth 5045
Product: Hot New Nail Products
Company/booth: Pet Head Inc. / Booth 5057
Product: Pet Dry Shampoo
Company/booth: BrookLands Inc. / Booth 3360
Company/booth: ChoiceMMed America Co / Booth 4749
Product: Lung Boost Respiratory Trainer
Household Products/Non-Edible Consumables
Company/booth: ShurTech Brands, LLC / Booth 3257
Product: Disney Licensed Duck Tape
Company/booth: Wahl Clipper Corp./ Booth 3058
Product: Grooms Man Trimmer
Pharmacy Operations Equipment & Services
Company/booth: AccessaMed, Inc. / Booth 5002
Product: Digital Audio Label
Company/booth: Mylan Inc. / Booth 3426
Product: EpiPen Jr.
Company/booth: IMPLUS Foot Care / Booth 3349
Product: Little Hotties Warmers
CareMed selected to distribute Tarceva
LAKE SUCCESS, N.Y. — Specialty pharmacy CareMed Pharmaceutical Services has been added to a limited-distribution network for a cancer drug sold by Genentech and Astellas Pharma, the company said.
CareMed said it had been selected to supply the drug, Tarceva (erlotinib). The two drug makers stopped distributing the drug, a once-daily treatment for advanced lung cancer, through retail pharmacies at the beginning of July.
"CareMed is honored to be able to continue supplying our patients with Tarceva," CareMed SVP sales and marketing John Witkowski said. "In 2013, the American Cancer Society estimates 228,000 Americans will be diagnosed with lung cancer, with [non-small cell lung cancer] accounting for 85% of lung cancer cases. Of these, the majority of people diagnosed will already be in an advanced stage of the disease."